Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?
Novo Nordisk is seeking to regain its competitive edge in the GLP-1 weight-loss market through a new partnership with Vivani Medical. The company aims to overcome the limitations of current injectable treatments by developing more convenient delivery methods to compete with Eli Lilly.
Why it matters
The competition between Novo Nordisk and Eli Lilly is driving rapid innovation in the multi-billion dollar weight-loss drug market.
Novo Nordisk ( NVO -1.41% ) started the GLP-1 weight-loss revolution that is sweeping the world. Its Wegovy/Ozempic shot was so popular that the company couldn't keep up with demand. That proved to be a major problem for the company, particularly after competitor Eli Lilly ( LLY -0.13% ) introduced its own GLP-1 weight-loss drug, Zepbound/Mounjaro, which enabled greater weight loss.
But Novo Nordisk has been fighting back. Right now, that's all about its Wegovy pill. But a new partnership with Vivani Medical ( VANI +1.43% ) could flip the script on the entire GLP-1 industry.
The healthcare industry is highly innovative and highly competitive. It isn't surprising at all that Novo Nordisk's early success in the GLP-1 weight-loss niche didn't last. But the fact that Eli Lilly introduced a more desirable GLP-1 product should not be taken as an indication that it has a permanent lead.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in